Medco Research submits NDA for ViaScint

Article

Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients

Radiopharmaceutical developer Medco Research last month fileda new drug application for its ViaScint cardiac imaging agent.ViaScint is designed to predict changes in global ventricularfunction after coronary revascularization in patients undergoingcoronary artery bypass grafting (SCAN 1/17/96). Medco Research,of Research Triangle Park, NC, also developed cardiac stress agentAdenoscan, which is marketed by Fujisawa.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.